UK – NICE changes its mind on Perjeta

The National Institute for Health and Care Excellence (NICE) draft guidance has recommended Roche’s Perjeta (pertuzumab) for a new breast cancer indication, after an improved price offer from the company.

The recommendation is for treating early HER2-positive breast cancer in people who have had surgery, and whose cancer has already spread to their lymph nodes (node-positive disease).

The drug given with Herceptin (trastuzumab) and chemotherapy is already recommended for treating early HER2-positive breast cancer before surgery (neo-adjuvant use). Also with Herceptin and Taxotere (docetaxel) for treating HER2-positive breast cancer that has either recurred in the breast following initial treatment or has spread from the breast to elsewhere in the body…